Author

A. Parsyan

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Combination of Radiation Treatment and PLK4-Inhibitor, CFI-400945, Leads to Upregulation of ICAM-1, STAT3 Activation, and Cellular Senescence in TNBC

Triple-negative breast cancer (TNBC) is one of the most aggressive and highly metastatic subtypes of breast cancer. It lacks canonical biomarkers and is often resistant to treatments, including radiotherapy (RT). This mandates the development of better treatments through identifying novel therapeutic targets and bi...

Isabel Kannampuzha, Vasudeva Bhat, Sugitha Janarthanan et al. · Breast Cancer: Basic and Cli... · 0 citations

Review Open access Oct 2026

Neurofibromin in Breast Cancer.

Breast cancer is one of the most common lethal malignancies in women. Identifying new molecular vulnerabilities to develop clinically actionable biomarkers and targeted treatments to improve patient outcomes is crucial in this disease. In recent years, neurofibromin (NF1), encoded by the neurofibromin 1 gene (NF1), who...

A. Parsyan · Critical reviews in oncology... · 0 citations

Open access Sep 2026

Exploratory Transcriptomic Profiling of Triple-Negative Breast Cancer Patient-Derived Organoids Following Treatment with Radiation Alone and in Combination with Polo-like Kinase 4 Inhibition

Identification of novel biomarkers in triple-negative breast cancer (TNBC), one of the most aggressive breast cancer subtypes, is of critical clinical importance. Although radiation treatment (RT) is a cornerstone of TNBC treatment, resistance to RT compromises its therapeutic efficacy. Combining RT with radiosensitizi...

Sugitha Janarthanan, Isabel Kannampuzha, Harjot Athwal et al. · Radiation · 0 citations